Nestor Tomycz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nestor Tomycz has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Stephen Jaffee
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, United States
9 shared publications - Trent Kite
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, United States
6 shared publications - Dorian Mateusz Kusyk
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, Pennsylvania, United States
4 shared publications - Donald Whiting
Allegheny General Hospital, Pittsburgh, Pennsylvania
3 shared publications - Michael Patterson
Center for Pain Relief, Allegheny Health Network, McMurray, United States
3 shared publications - Chinelo Onyiah
Department of Neurosurgery, Allegheny Health Network, Pittsburgh, United States
2 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 324
BurstDR spinal cord stimulation for chronic regional pain syndrome secondary to Castleman’s disease treatment: A case report
Background: Castleman’s disease is a rare lymphoproliferative disorder that can affect lymph nodes anywhere in the body. Removal of the enlarged lymph nodes may lead to secondary nerve damage, potentially resulting in patients developing complex regional pain syndrome (CRPS) type 2. Spinal cord stimulation (SCS) is a well-established, cost-effective therapy for chronic refractory pain, including CRPS type 2. Case Description: A 32-year-old female who was treated for unicentric hyaline vascular type Castleman’s disease. Following neurolysis, she developed CRPS type 2 of the lumbosacral plexus; her symptoms persisted despite pharmacotherapy and physical therapy. She underwent a trial of burst SCS with significant symptom relief, followed by permanent implantation of a Penta paddle lead at the T8 level. Three months postoperatively, she reported marked clinical improvement and was able to discontinue pregabalin. Conclusion: A 32-year-old female with Castleman’s disease developed CRPS type 2 secondary to neurolysis that was effectively treated with Burst SCS.
- 29 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 324
Open AccessBurstDR spinal cord stimulation for chronic regional pain syndrome secondary to Castleman’s disease treatment: A case report
Background: Castleman’s disease is a rare lymphoproliferative disorder that can affect lymph nodes anywhere in the body. Removal of the enlarged lymph nodes may lead to secondary nerve damage, potentially resulting in patients developing complex regional pain syndrome (CRPS) type 2. Spinal cord stimulation (SCS) is a well-established, cost-effective therapy for chronic refractory pain, including CRPS type 2. Case Description: A 32-year-old female who was treated for unicentric hyaline vascular type Castleman’s disease. Following neurolysis, she developed CRPS type 2 of the lumbosacral plexus; her symptoms persisted despite pharmacotherapy and physical therapy. She underwent a trial of burst SCS with significant symptom relief, followed by permanent implantation of a Penta paddle lead at the T8 level. Three months postoperatively, she reported marked clinical improvement and was able to discontinue pregabalin. Conclusion: A 32-year-old female with Castleman’s disease developed CRPS type 2 secondary to neurolysis that was effectively treated with Burst SCS.
- Open Access
- 29 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 325
Caretaker views on deep brain stimulation for cognitively impaired patients with Parkinson’s disease
Background: : Neuropsychological assessment is crucial in the presurgical evaluation of patients with Parkinson’s disease (PD) who are contemplating deep-brain stimulation (DBS). No standardized screening test battery currently exists. Our movement disorder group most frequently employs the Mattis dementia rating scale (MDRS) and usually advises against DBS for PD patients with MDRS ≤130. We reviewed patient-reported outcomes and satisfaction with DBS in these borderline patients. Methods: We retrospectively reviewed a single-center database of 696 DBS patients to identify individuals with PD and an MDRS score ≤130. Telephone interviews were conducted with the patient’s primary caretaker (PCT) to assess long-term satisfaction with the procedure. Electronic medical records were reviewed to analyze patient demographics, preoperative assessments, and surgical complications. Results: We identified 19 DBS patients and interviewed 6 PCTs. Five (83%) PCTs reported they were “very satisfied” with long-term DBS outcomes, and one (17%) reported they were “satisfied.” All PCTs reported improved patient quality of life and motor symptoms, would urge their loved one to undergo surgery again, and have recommended DBS surgery to others. Three PCTs reported eventual worsened cognition, while one reported improved cognition. Conclusion: A MDRS score ≤130 by itself does not preclude a poor outcome with DBS for PD. A standardized battery of preoperative neuropsychological testing for DBS is needed to establish better evidenced-based “cutoff ” scores and to improve candidate selection.
- 29 May 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 325
Open AccessCaretaker views on deep brain stimulation for cognitively impaired patients with Parkinson’s disease
Background: : Neuropsychological assessment is crucial in the presurgical evaluation of patients with Parkinson’s disease (PD) who are contemplating deep-brain stimulation (DBS). No standardized screening test battery currently exists. Our movement disorder group most frequently employs the Mattis dementia rating scale (MDRS) and usually advises against DBS for PD patients with MDRS ≤130. We reviewed patient-reported outcomes and satisfaction with DBS in these borderline patients. Methods: We retrospectively reviewed a single-center database of 696 DBS patients to identify individuals with PD and an MDRS score ≤130. Telephone interviews were conducted with the patient’s primary caretaker (PCT) to assess long-term satisfaction with the procedure. Electronic medical records were reviewed to analyze patient demographics, preoperative assessments, and surgical complications. Results: We identified 19 DBS patients and interviewed 6 PCTs. Five (83%) PCTs reported they were “very satisfied” with long-term DBS outcomes, and one (17%) reported they were “satisfied.” All PCTs reported improved patient quality of life and motor symptoms, would urge their loved one to undergo surgery again, and have recommended DBS surgery to others. Three PCTs reported eventual worsened cognition, while one reported improved cognition. Conclusion: A MDRS score ≤130 by itself does not preclude a poor outcome with DBS for PD. A standardized battery of preoperative neuropsychological testing for DBS is needed to establish better evidenced-based “cutoff ” scores and to improve candidate selection.
- Open Access
- 10 October 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 430
BurstDR spinal cord stimulation for chronic inflammatory demyelinating polyneuropathy
Background: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder in which the immune system attacks the myelin sheath, leading to progressive muscle weakness and sensory loss. Neuropathic pain is a common and often debilitating symptom in patients with CIDP. Treatment options include immunoglobulin therapy and, in refractory cases, spinal cord stimulation (SCS). Case Description: We present the case of a 70-year-old male with CIDP who experienced severe neuropathic pain in a stocking distribution affecting both lower extremities. He had previously been treated with intravenous immunoglobulin with limited relief of his pain symptoms. Due to persistent, debilitating neuropathic pain despite ongoing immunotherapy, he underwent implantation of a thoracic paddle spinal cord stimulator. At 3-month postoperative follow-up, he reported a 75% reduction in pain intensity. Conclusion: BurstDR paddle lead SCS may offer significant pain relief in patients with CIDP-associated neuropathic pain and should be considered as part of a multidisciplinary treatment.
- 10 October 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 430
Open AccessBurstDR spinal cord stimulation for chronic inflammatory demyelinating polyneuropathy
Background: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder in which the immune system attacks the myelin sheath, leading to progressive muscle weakness and sensory loss. Neuropathic pain is a common and often debilitating symptom in patients with CIDP. Treatment options include immunoglobulin therapy and, in refractory cases, spinal cord stimulation (SCS). Case Description: We present the case of a 70-year-old male with CIDP who experienced severe neuropathic pain in a stocking distribution affecting both lower extremities. He had previously been treated with intravenous immunoglobulin with limited relief of his pain symptoms. Due to persistent, debilitating neuropathic pain despite ongoing immunotherapy, he underwent implantation of a thoracic paddle spinal cord stimulator. At 3-month postoperative follow-up, he reported a 75% reduction in pain intensity. Conclusion: BurstDR paddle lead SCS may offer significant pain relief in patients with CIDP-associated neuropathic pain and should be considered as part of a multidisciplinary treatment.
- Open Access
- 22 August 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 355
Deep brain stimulation for Meige syndrome
Background: Meige syndrome is a cranial dystonia which presents with blepharospasm and oromandibular dystonia, identified in patients with Parkinson’s disease, atypical Parkinsonism, and essential tremor. Treatment of Meige syndrome involves both pharmacological and surgical interventions including botulinum toxin injections, muscle relaxants, dopamine receptor antagonists, and anticholinergic drugs. Deep brain stimulation (DBS) has also been used to treat these patients with medically refractory Meige syndrome with a high degree of efficacy. Herein, we present a case of medically refractory Meige syndrome treated with bilateral globus pallidus internus (GPi) DBS with improvement of dystonia. Case Description: This is a 74-year-old female diagnosed with blepharospasm 15 years ago, after she noted increased blinking frequency and difficulty keeping her eyelids open. She was initially managed with extraocular Botox injections, but her symptoms progressed and began to include shoulder shrugging, jaw clenching, and uncontrolled head turning. A diagnosis of Meige syndrome was made and the patient responded appropriately to pharmacological management with benzodiazepines, baclofen, and carbidopa-levodopa. The patient eventually developed severe dystonia secondary to her Meige syndrome diagnosis and her symptoms were now refractory to botulinum toxin injections and medications. The patient underwent DBS of the bilateral GPi. After 52 weeks of follow-up, significant improvements in involuntary blinking, squinting, photophobia, teeth clenching, and neck tightness were noted. Conclusion: DBS is a safe and effective means of treating dystonia related to Meige syndrome. Further studies are needed to elucidate optimal targeting for these patients and programming specifics for long-term outcomes.
- 22 August 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 355
Open AccessDeep brain stimulation for Meige syndrome
Background: Meige syndrome is a cranial dystonia which presents with blepharospasm and oromandibular dystonia, identified in patients with Parkinson’s disease, atypical Parkinsonism, and essential tremor. Treatment of Meige syndrome involves both pharmacological and surgical interventions including botulinum toxin injections, muscle relaxants, dopamine receptor antagonists, and anticholinergic drugs. Deep brain stimulation (DBS) has also been used to treat these patients with medically refractory Meige syndrome with a high degree of efficacy. Herein, we present a case of medically refractory Meige syndrome treated with bilateral globus pallidus internus (GPi) DBS with improvement of dystonia. Case Description: This is a 74-year-old female diagnosed with blepharospasm 15 years ago, after she noted increased blinking frequency and difficulty keeping her eyelids open. She was initially managed with extraocular Botox injections, but her symptoms progressed and began to include shoulder shrugging, jaw clenching, and uncontrolled head turning. A diagnosis of Meige syndrome was made and the patient responded appropriately to pharmacological management with benzodiazepines, baclofen, and carbidopa-levodopa. The patient eventually developed severe dystonia secondary to her Meige syndrome diagnosis and her symptoms were now refractory to botulinum toxin injections and medications. The patient underwent DBS of the bilateral GPi. After 52 weeks of follow-up, significant improvements in involuntary blinking, squinting, photophobia, teeth clenching, and neck tightness were noted. Conclusion: DBS is a safe and effective means of treating dystonia related to Meige syndrome. Further studies are needed to elucidate optimal targeting for these patients and programming specifics for long-term outcomes.
- Open Access
- 1 August 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 318
Burst-type deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: A case series on tolerability and efficacy
Background: Deep brain stimulation (DBS) has become an evidence-based treatment for movement disorders such as Parkinson’s disease (PD). Recent animal studies of DBS suggest that burst-type DBS may specifically activate neuronal subpopulations and that this type of electrical stimulation programing may improve the efficacy and durability of DBS. Burst type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered. Implanted pulse generators can deliver such stimulation by setting specific “on” and “off ” times; however, there is limited published human data on the results of such programming in patients undergoing DBS for movement disorders such as PD. Herein, we discuss our experience using burst-type DBS of the bilateral subthalamic nucleus (STN) in PD in two patients. Case Description: We conducted a case series with two patients implanted with bilateral STN DBS, tested the burst intermittent stimulation parameters, and assessed United Parkinson’s Disease Rating Scale scores to determine the effect of therapy and patient tolerance. A 72-year-old man with bilateral STN DBS for bradykinesia/rigidity predominant PD tolerated the burst pattern stimulation for a total of 1 year; parameters were changed within this period, and he was ultimately switched back to continuous stimulation after the 1-year mark. The second patient, a 65-year-old man with bilateral STN DBS for tremor predominant PD, started on the Burst protocol but immediately did not tolerate the programming change due to a significant recurrence of tremor and was subsequently switched to a continuous cycle. Conclusion: Burst programming provided variable results in therapeutic effect for the patient’s bilateral STN DBS of differing Parkinson’s phenotypes. Further investigation is needed to assess the efficacy of various programming modalities for patients with PD.
- 1 August 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 318
Open AccessBurst-type deep brain stimulation of the subthalamic nucleus in Parkinson’s disease: A case series on tolerability and efficacy
Background: Deep brain stimulation (DBS) has become an evidence-based treatment for movement disorders such as Parkinson’s disease (PD). Recent animal studies of DBS suggest that burst-type DBS may specifically activate neuronal subpopulations and that this type of electrical stimulation programing may improve the efficacy and durability of DBS. Burst type DBS is defined as a novel stimulation protocol in which intermittent bursts of traditional high-frequency rectangular wave stimulation are delivered. Implanted pulse generators can deliver such stimulation by setting specific “on” and “off ” times; however, there is limited published human data on the results of such programming in patients undergoing DBS for movement disorders such as PD. Herein, we discuss our experience using burst-type DBS of the bilateral subthalamic nucleus (STN) in PD in two patients. Case Description: We conducted a case series with two patients implanted with bilateral STN DBS, tested the burst intermittent stimulation parameters, and assessed United Parkinson’s Disease Rating Scale scores to determine the effect of therapy and patient tolerance. A 72-year-old man with bilateral STN DBS for bradykinesia/rigidity predominant PD tolerated the burst pattern stimulation for a total of 1 year; parameters were changed within this period, and he was ultimately switched back to continuous stimulation after the 1-year mark. The second patient, a 65-year-old man with bilateral STN DBS for tremor predominant PD, started on the Burst protocol but immediately did not tolerate the programming change due to a significant recurrence of tremor and was subsequently switched to a continuous cycle. Conclusion: Burst programming provided variable results in therapeutic effect for the patient’s bilateral STN DBS of differing Parkinson’s phenotypes. Further investigation is needed to assess the efficacy of various programming modalities for patients with PD.
- Open Access
- 6 June 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 222
BurstDR™ spinal cord stimulation for chemotherapy-induced peripheral neuropathy
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common persistent adverse effects of chemotherapy affecting cancer survivors. Other than the use of duloxetine, no other intervention has a proven benefit for these patients. Here, a patient with multiple myeloma who developed CIPN experienced a significant reduction in their symptoms after the implantation of a spinal cord stimulator. Case Description: A 64-year-old male with a history of multiple myeloma presented with chronic pain 4 years after chemotherapy, followed by an autologous stem cell transplant. As the patient’s symptoms were refractory to medical management, he underwent placement of a permanent spinal cord stimulator, resulting in 80% relief of calf pain and a 60% improvement in foot paresthesias/pain. Conclusion: Spinal cord stimulation proved effective in treating CIPN (CIPN following autologous stem cell transplant) in a 64-year-old male treated 4 years ago for multiple myeloma.
- 6 June 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 222
Open AccessBurstDR™ spinal cord stimulation for chemotherapy-induced peripheral neuropathy
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common persistent adverse effects of chemotherapy affecting cancer survivors. Other than the use of duloxetine, no other intervention has a proven benefit for these patients. Here, a patient with multiple myeloma who developed CIPN experienced a significant reduction in their symptoms after the implantation of a spinal cord stimulator. Case Description: A 64-year-old male with a history of multiple myeloma presented with chronic pain 4 years after chemotherapy, followed by an autologous stem cell transplant. As the patient’s symptoms were refractory to medical management, he underwent placement of a permanent spinal cord stimulator, resulting in 80% relief of calf pain and a 60% improvement in foot paresthesias/pain. Conclusion: Spinal cord stimulation proved effective in treating CIPN (CIPN following autologous stem cell transplant) in a 64-year-old male treated 4 years ago for multiple myeloma.
- Open Access
- 6 June 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 227
Delayed epidural hematoma after spinal cord stimulator implantation in a patient with von Willebrand disease: Illustration
Background: A patient with von Willebrand disease developed a delayed epidural hematoma originating from the tunneling tract and gluteal generator pocket following the placement of a thoracic spinal cord stimulator (SCS). Case Description: A 43-year-old male with von Willebrand disease underwent thoracic SCS placement to treat chronic bilateral lower extremity pain with paresthesias in 2024. The patient had previously experienced a postoperative hematoma in 2010. At the time of the thoracic SCS placement, he received 7 days of prophylactic antihemophilic factor/von Willebrand factor complex therapy. One month following placement of the thoracic SCS, the patient noted significant swelling localized to the thoracic and buttock incisions. Exploratory surgery documented an additional hematoma tracking from the tunneling tract and gluteal generator pocket all the way into the epidural space; it was promptly removed. At the 6-month follow-up, he exhibited no further wounds or neurological issues. Conclusion: Patients with coagulopathies, and critically, von Willebrand disease, undergoing SCS placement are at increased risk for postoperative hematomas.
- 6 June 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 227
Open AccessDelayed epidural hematoma after spinal cord stimulator implantation in a patient with von Willebrand disease: Illustration
Background: A patient with von Willebrand disease developed a delayed epidural hematoma originating from the tunneling tract and gluteal generator pocket following the placement of a thoracic spinal cord stimulator (SCS). Case Description: A 43-year-old male with von Willebrand disease underwent thoracic SCS placement to treat chronic bilateral lower extremity pain with paresthesias in 2024. The patient had previously experienced a postoperative hematoma in 2010. At the time of the thoracic SCS placement, he received 7 days of prophylactic antihemophilic factor/von Willebrand factor complex therapy. One month following placement of the thoracic SCS, the patient noted significant swelling localized to the thoracic and buttock incisions. Exploratory surgery documented an additional hematoma tracking from the tunneling tract and gluteal generator pocket all the way into the epidural space; it was promptly removed. At the 6-month follow-up, he exhibited no further wounds or neurological issues. Conclusion: Patients with coagulopathies, and critically, von Willebrand disease, undergoing SCS placement are at increased risk for postoperative hematomas.
- Open Access
- 18 April 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 139
Dermatologic manifestations of complex regional pain syndrome improved after dorsal root ganglion stimulation
Background: Complex regional pain syndrome is a condition that causes autonomic dysfunction, including severe pain, swelling, temperature fluctuations, and cutaneous flushing. Case Description: The patient was a 38-year-old woman with complex regional pain syndrome type I of the right foot that developed after a work-related accident. At the time of presentation, she complained of a stabbing and burning pain, which subjectively felt like extreme warmth for 6 weeks. On physical examination, she presented with diffuse cutaneous flushing, erythema, nonpitting edema, skin mottling of the medial aspect of the right foot and ankle, a purple macule on the right inferomedial aspect of the great toe, and a purple patch on the inferomedial aspect of the heel. The patient underwent right-sided L5/S1 open dorsal root ganglion (DRG) stimulation under the care of neurological surgery. Postprocedurally, the cutaneous flushing, erythema, edema, mottling, purple macule, and patch had completely resolved. At the 1-year postoperative appointment, the patient continued to have a significant improvement in her preoperative pain and notably improved allodynia, flushing, mottling, and temperature sensitivity. Conclusion: We have described the successful resolution of complex regional pain syndrome associated dermatologic manifestations in the setting of DRG stimulation. To our knowledge, a case of this nature has yet to be described in the literature.
- 18 April 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 139
Open AccessDermatologic manifestations of complex regional pain syndrome improved after dorsal root ganglion stimulation
Background: Complex regional pain syndrome is a condition that causes autonomic dysfunction, including severe pain, swelling, temperature fluctuations, and cutaneous flushing. Case Description: The patient was a 38-year-old woman with complex regional pain syndrome type I of the right foot that developed after a work-related accident. At the time of presentation, she complained of a stabbing and burning pain, which subjectively felt like extreme warmth for 6 weeks. On physical examination, she presented with diffuse cutaneous flushing, erythema, nonpitting edema, skin mottling of the medial aspect of the right foot and ankle, a purple macule on the right inferomedial aspect of the great toe, and a purple patch on the inferomedial aspect of the heel. The patient underwent right-sided L5/S1 open dorsal root ganglion (DRG) stimulation under the care of neurological surgery. Postprocedurally, the cutaneous flushing, erythema, edema, mottling, purple macule, and patch had completely resolved. At the 1-year postoperative appointment, the patient continued to have a significant improvement in her preoperative pain and notably improved allodynia, flushing, mottling, and temperature sensitivity. Conclusion: We have described the successful resolution of complex regional pain syndrome associated dermatologic manifestations in the setting of DRG stimulation. To our knowledge, a case of this nature has yet to be described in the literature.
- Open Access
- 18 April 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 144
Erroneous intramedullary placement of spinal cord stimulator: A case report and review of the literature
Background: Spinal cord stimulation is a common treatment for patients with medically refractory chronic neuropathic pain. Before permanent implantation of spinal cord stimulation, patients will undergo a percutaneous trial to ensure the efficacy of the treatment modality and determine the optimal location of placement. While complications from this procedure are rare, there are reports in the literature of infection, epidural hematoma, and even paralysis. There are few reports of percutaneous leads tracking through the spinal cord itself, and subsequently, few reports of management should such a complication take place. Herein, we provide an example of such a phenomenon with no significant postoperative complications, morbidity, or mortality. Case Description: A retrospective chart review was completed utilizing the electronic medical record. Data gathered included patient demographics, oncological history, medications, imaging, and operative reports. This is a 64–year-old male with a history of with a history of a traumatic brachial plexus avulsion and right upper extremity amputation at the shoulder after a motorcycle accident approximately 20 years prior presented to our institution with left upper extremity paresthesias, gain imbalance, and urinary incontinence after a permanent percutaneous spinal cord stimulation lead was placed from an outside institution. The patient was found to have the lead tracking through the intramedullary space of his spinal cord. The patient was taken to the operating room for removal of the lead and had no significant complications during his postoperative course. Conclusion: There is a paucity of literature regarding the removal of an intramedullary percutaneous spinal cord stimulator lead; herein, we present such a case.
- 18 April 2025
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 16, 144
Open AccessErroneous intramedullary placement of spinal cord stimulator: A case report and review of the literature
Background: Spinal cord stimulation is a common treatment for patients with medically refractory chronic neuropathic pain. Before permanent implantation of spinal cord stimulation, patients will undergo a percutaneous trial to ensure the efficacy of the treatment modality and determine the optimal location of placement. While complications from this procedure are rare, there are reports in the literature of infection, epidural hematoma, and even paralysis. There are few reports of percutaneous leads tracking through the spinal cord itself, and subsequently, few reports of management should such a complication take place. Herein, we provide an example of such a phenomenon with no significant postoperative complications, morbidity, or mortality. Case Description: A retrospective chart review was completed utilizing the electronic medical record. Data gathered included patient demographics, oncological history, medications, imaging, and operative reports. This is a 64–year-old male with a history of with a history of a traumatic brachial plexus avulsion and right upper extremity amputation at the shoulder after a motorcycle accident approximately 20 years prior presented to our institution with left upper extremity paresthesias, gain imbalance, and urinary incontinence after a permanent percutaneous spinal cord stimulation lead was placed from an outside institution. The patient was found to have the lead tracking through the intramedullary space of his spinal cord. The patient was taken to the operating room for removal of the lead and had no significant complications during his postoperative course. Conclusion: There is a paucity of literature regarding the removal of an intramedullary percutaneous spinal cord stimulator lead; herein, we present such a case.
- Open Access
- 12 March 2025
- Published by Elsevier in Interventional Pain Medicine
- Vol. 4 (1) , 100571
A scoping review of spinal cord stimulation for phantom limb pain
- 12 March 2025
- Published by Elsevier in Interventional Pain Medicine
- Vol. 4 (1) , 100571
Open AccessA scoping review of spinal cord stimulation for phantom limb pain